Literature DB >> 7933834

Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs.

L Gaber1, C Walton, S Brown, G Bakris.   

Abstract

We previously reported the renal hemodynamic effects of different antihypertensive regimens in uninephrectomized, alloxan-induced, diabetic (DM) beagle dogs following one year of treatment. Dogs were prospectively randomized to one of five groups (N = 26): nondiabetic controls, Group I; dogs with DM on no antihypertensive drugs, Group II; dogs on a converting enzyme inhibitor, lisinopril (L), Group III; dogs on a calcium antagonist, TA3090 (diltiazem-like), Group IV; and dogs on a combination of each drug, in reduced doses, Group V. The current paper extends our previous studies by describing the morphologic changes that occurred within each group of dogs studied. More than 100 glomeruli from the renal cortex of each dog were evaluated for increases in mesangial volume fraction (Vv), glomerulosclerosis (GS) and ateriolar hyalinosis. The interstitium was also evaluated for associated changes. Increases in Vv were attenuated in all treated groups (0.28 +/- 0.04, DM alone versus 0.16 +/- 0.05 L; 0.21 +/- 0.07, TA-3090; 0.19 +/- 0.06 micron 2/micron 2, L+TA 3090; P < 0.05) compared to untreated DM. An attenuated increase in Vv also correlated with a blunted rise in proteinuria in Groups III (r = 0.79) and V (r = 0.81) but not Group IV (r = 0.29). Development of focal GS was blunted in all treated groups; however, global GS was fourfold greater in Group IV compared to untreated DM. The degree of interstitial fibrosis also correlated with the degree of global GS. These data support the concept that both a converting enzyme inhibitor and heart rate lowering calcium antagonist attenuate morphologic progression of diabetic renal disease.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7933834     DOI: 10.1038/ki.1994.255

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  10 in total

Review 1.  Dihydropyridine calcium channel blockers and renal disease.

Authors:  Nicolás R Robles; Francesco Fici; Guido Grassi
Journal:  Hypertens Res       Date:  2016-07-14       Impact factor: 3.872

2.  Canine and equine mesangial cells in vitro.

Authors:  D Ennulat; S A Brown
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-09       Impact factor: 2.416

3.  Anti-proliferative actions of T-type calcium channel inhibition in Thy1 nephritis.

Authors:  Andrea Cove-Smith; Christopher J Mulgrew; Olena Rudyk; Neelanjana Dutt; Linda M McLatchie; Michael J Shattock; Bruce M Hendry
Journal:  Am J Pathol       Date:  2013-06-05       Impact factor: 4.307

4.  The case for combining angiotensin-converting enzyme inhibitors and calcium-channel blockers.

Authors:  A A Taylor; S Sunthornyothin
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

5.  Calcium-channel blockers and the progression of renal disease.

Authors:  K A Griffin; A K Bidani
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

Review 6.  Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction.

Authors:  George L Bakris; James R Sowers
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

Review 7.  Drug treatment of hypertension complicating diabetes mellitus.

Authors:  M J MacLeod; J McLay
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

8.  Amlodipine Reduces Inflammation despite Promoting Albuminuria in the Streptozotocin-Induced Diabetic Rat.

Authors:  Elizabeth R Flynn; David C Marbury; R Taylor Sawyer; Jonathan Lee; Christine Teutsch; Katalin Kauser; Christine Maric-Bilkan
Journal:  Nephron Extra       Date:  2012-07-06

9.  Longitudinal prevalence of hypertension, proteinuria, and retinopathy in dogs with spontaneous diabetes mellitus.

Authors:  I P Herring; D L Panciera; S R Werre
Journal:  J Vet Intern Med       Date:  2014-01-13       Impact factor: 3.333

10.  ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats.

Authors:  Mark J Acierno; Scott Brown; Amanda E Coleman; Rosanne E Jepson; Mark Papich; Rebecca L Stepien; Harriet M Syme
Journal:  J Vet Intern Med       Date:  2018-10-24       Impact factor: 3.333

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.